Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

Drug Distribution: Plasma Protein Binding

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...

Drug Distribution: Tissue Binding

Drug Distribution: Tissue Binding

Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...

Modified-Release Drug Delivery Systems: Bioavailability

Modified-Release Drug Delivery Systems: Bioavailability

Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Economic impact of managing invasive mold disease with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Spain.

Expert review of anti-infective therapy·2024

Same author

Recommendations on the use of azole antifungals in hematology-oncology patients.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2023

Same author

Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2022

Same author

Simplified risk-prediction for benchmarking and quality improvement in emergency general surgery. Prospective, multicenter, observational cohort study.

International journal of surgery (London, England)·2021

Same author

Differential diagnosis of posterior compartment prolapse using transperineal ultrasound.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2021

Same author

Recommendations for antibiotic selection for severe nosocomial infections.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2021

Search research articles

Related Experiment Video

Updated: May 12, 2026

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

Published on: September 9, 2015

Oral availability of bilastine.

B Sádaba¹, A Gómez-Guiu, J R Azanza

¹Clinical Research Unit, Servicio de Farmacología Clínica, Clínica Universidad de Navarra, c/Pío XII, n° 36, 31008, Pamplona, Navarra, Spain. bsadaba@unav.es

Clinical Drug Investigation

|March 27, 2013

Summary

This summary is machine-generated.

Bilastine, a non-sedating antihistamine, demonstrated moderate oral bioavailability of 60.67% in healthy adults. This study assessed the absorption of bilastine following oral administration.

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Related Experiment Videos

Last Updated: May 12, 2026

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

Published on: September 9, 2015

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Area of Science:

Pharmacology
Clinical Pharmacology

Background:

Bilastine is a novel, non-sedating H1 receptor antagonist for allergic rhinitis and urticaria.
Clinical trials have established the efficacy and safety of bilastine.

Purpose of the Study:

To determine the absolute oral bioavailability of bilastine in humans.
To characterize the pharmacokinetic profile of bilastine after oral administration.

Main Methods:

A randomized, single-dose, open-label, two-arm crossover study.
Twelve healthy adults received either a 20-mg oral tablet or a 10-mg intravenous formulation of bilastine.
Blood and urine samples were collected for pharmacokinetic analysis.

Main Results:

The absolute oral bioavailability of bilastine was determined to be 60.67%.
The maximum concentration of bilastine occurred at 1.31 hours post-oral administration.
Pharmacokinetic parameters were consistent with previous findings, and the drug was well-tolerated.

Conclusions:

Bilastine is rapidly absorbed after oral administration in healthy subjects.
The absolute oral bioavailability of bilastine is moderate.